Background: Melasma is a highly prevalent hyperpigmentation disorder with a
| INTRODUCTION
Melasma, the commonest acquired hyperpigmentation in women, affects mainly the ultraviolet (UV) exposed areas particularly forehead, cheeks, temples, and upper lip. It has a negative impact on the psychological state and quality of life of the affected patients. Multiple factors are implicated in the pathogenesis of melasma; however, the definite underlying mechanisms are not yet completely established. Ultraviolet exposure is one of the main etiological factors, besides genetic and hormonal factors. [1] [2] [3] Hypermelanosis caused by UV radiation might be attributed to increasing melanocyte activity and peroxidation of cell membrane lipids with production of free radicals that stimulate excess melanin production. It has been suggested that oxidative stress plays an important role in the pathogenesis of melasma. Different anti-oxidants such as vitamin E, niacinamide, and vitamin C have been used in the treatment of melasma especially due to their inhibitory effect on free radicals, which trigger melanin synthesis. [4] [5] [6] Silymarin is derived from the milk thistle plant "Silybum marianum." Silibinin, the main component of silymarin, has been found to have antioxidant properties. It decreases the hazardous effects of solar ultraviolet radiation and significantly prevents melanin production in a dose-dependent manner without effect on cell viability. 7, 8 Hydroquinone (HQ) is the most popular and most extensively studied medication in the management of melasma. It inhibits melanogenesis by inhibiting tyrosinase enzyme, affects the formation, melanization, and degradation of melanosomes and modulates the membranous structures of melanocytes, causing necrosis of whole melanocytes. Hydroquinone is, however, associated with frequent adverse effects that stimulate the research for other agents with equal efficacy and more safety.
9,10 Herein, we evaluate the efficacy and safety of topical silymarin, at different concentrations, versus hydroquinone 4% in the treatment of melasma.
| PATIENTS AND METHODS

| Patients
Forty-two adult female patients with melasma of different durations, severities, patterns and types were included in the study. Exclusion criteria included pregnancy, breast feeding, coexistence of diseases associated with hyperpigmentation such as Addison disease, concomitant use of drugs that may induce hyperpigmentation such as oral contraceptives, and treatment of melasma within the last month before enrolment. The study has been approved by the local Institutional Review Board, and an informed consent was taken from each patient before participation in the study.
All patients were subjected to through history taking, including onset and duration of melasma, family history, relation to pregnancy, relation to sun exposure, history of systemic diseases, and previous treatments. Complete dermatological examination was also performed to assess Fitzpatrick skin type, pattern of melasma (centro-facial, malar, or mandibular), melasma type (epidermal, dermal, or mixed) and severity as assessed by melasma area and severity index score (MASI Score). 4 The severity of melasma was divided according to MASI score into mild (1-16), moderate (>16-32), and severe (>32-48).
| Methods
The patients were divided into 3 equal groups, each contained 14 patients. Group 1 received silymarin 0.7% cream, group 2 received silymarin 1.4% cream and group 3 received hydroquinone 4% cream.
Silymarin was applied twice daily, while HQ was used once daily at night. The duration of treatment was 3 months in the 3 studied groups.
Silymarin cream was prepared in the Faculty of Pharmacy, Zagazig University, Egypt according to the following formulation: stearic acid 15 g, glycerin 5 g, KOH 0.72 g, H2O 79 g, sodium benzoate (0.1%), and Tween-80 (1%). Silymarin was added as 0.7% or 1.4%.
All patients were advised to avoid excessive sun exposure and to apply a broad spectrum sunscreen with a sun protection factor of at least 50. Digital color photographs were taking at baseline and every 2 weeks during treatment course. Adverse effects of the three treatment modalities were evaluated at each visit, and follow-up was performed every month for 6 months after the end of the treatment course to detect any recurrence of melasma.
| Statistical analysis
Data were checked, entered, and analyzed using SPSS (version 19).
Data were represented as mean ± SD for quantitative variables. Number and percentage were used for categorical variables. The one-way ANOVA test, chi-square test, and paired t test were used to assess the results. P values <0.05 was considered statistically significant.
| RESULTS
All the patients completed the study. Baseline characteristics of the studied patients are shown in Table 1 .There were no statistical significant differences between the three studied groups in the baseline characteristics, except for family history that was statistically higher in group 2 as compared to group 1 and 3. 
| In group 2 (silymarin 1.4% cream)
At baseline, the mean of MASI score was 21.75 ± 8.47, after 1 month it decreased to 17.39 ± 8.07, after 2 months it became 15.6 ± 7.92, at the end of treatment it became 14.88 ± 7.79%, and % of reduction in MASI score after treatment was 33.84 ± 15.61.
| In group 3 (hydroquinone 4% cream)
At baseline, the mean of MASI score was 16.64 ± 9.0, after 1 month it decreased to 12.25 ± 6.94, after 2 months it became 10.82 ± 7.10, at the end of treatment it became 8.81 ± 5.68%
and % of reduction in MASI score after treatment was 46.75 ± 22.83.
There was a statistically significant decrease in MASI score within the same group. Although the percent of reduction in MASI score was slightly higher in hydroquinone group, no statistically significant difference in MASI score between the three studied groups was found ( Table 2) . Assessment of the therapeutic response at different stages of treatment is shown in Table 3 and
| B: Patient satisfaction
There were no statistical significant differences between the three studied groups in patient satisfaction (Table 4) .
| Relationship between therapeutic response and different clinical variables
There was no statistical significant relationship between the therapeutic response and the different clinical variables in all groups.
T A B L E 1 Baseline characteristics of the studied patients 
| Adverse Effects
There was a statistically significant difference between HQ and silymarin groups in the reported adverse effects. HQ was associated with erythema in 10 patients (71.4%), burning in 10 patients (71.4%), scaling in 10 patients (71.4%), while no side effects were detected in both groups of silymarin.
| Follow up
Recurrence of melasma was observed in 1 patient (7.14%) in group 1, 1 patient (7.14%) in group 2, and 3 patients (21.4%) in group 3 after the 6-month follow-up period.
| DISCUSSION
Melasma is a highly prevalent hypermelanotic disorder in women although it can occur in men. It is often difficult to treat may be refractory to different therapeutic modalities and is commonly associated with a high relapsing rate. Principles of therapy include protection from UV rays, inhibition of melanocyte activity and melanin synthesis, and the disruption and removal of melanin granules. 8, 11 Topical therapy remains the mainstay of melasma treatment, with hydroquinone being the most popular and extensively studied agent.
In recent years, however, studies have shifted away from hydroquinone monotherapy to search for substances equal in efficacy but superior in safety. The epitome of a depigmenting agent should provide powerful, quick, yet selective lightening on the hyperactive melanocytes. Resultant elimination of unwanted pigment must be lasting, with no undesirable side effects. In spite of the presence of many topical therapeutic options, the ideal depigmenting agent has yet to be found. intradermal injection of tranexamic acid and glycolic acid peeling in the treatment of melasma. Their study revealed that the highest efficacy was observed in the group treated with glycolic acid peeling followed by silymarin group, and the least efficacy was reported in the group treated with intradermal injection of tranexamic acid.
Similarly, the results of the present study were in accordance with those demonstrated by Altaei 14 who reported significant improvement of melasma after treatment with silymarin (7 and 14 mg/mL). The author in this study used silymarin versus placebo, the duration of the study was 1 month only and no follow-up was performed. In our study, silymarin was used versus hydroquinone 4%, the duration of the study was 3 months and follow-up was performed every month for 6 months.
The exact mode of action of silymarin is not yet completely elucidated. Silibinin, the main component of silymarin, has powerful antioxidant and photoprotective effects. It minimizes the hazardous effects of UV radiation such as oxidative stress, inflammation, edema, erythema, DNA damage, and immune responses. Silymarin can also reduce melanin production by its antioxidant effect and inhibition of Ldopa oxidation activity of tyrosinase. In addition, it has been found that silymarin decreases the expression of tyrosinase protein. 7, 8 Hydroquinone has been proven as an effective treatment for melasma in a large number of previous studies. [15] [16] [17] [18] [19] [20] [21] This came in agreement with the results of the present study that revealed significant reduction of the severity of melasma after treatment with hydroquinone for 3 months. There was no statistically significant difference in the therapeutic response between silymarin-treated groups and hydroquinone group. This finding strongly suggests that silymarin might serve as a promising alternative to hydroquinone.
There was no statistical significant relationship between the therapeutic response in the three studied groups and the different clini- [15] [16] [17] [18] [19] [20] [21] These undesirable side effects arouse the need of an alternative safer modality, but with comparable efficacy to hydroquinone.
The absence of adverse effects in the patients treated with silymarin represents an important advantage of silymarin over the conventional hydroquinone that is commonly associated with the aforementioned adverse effects. This indicates that silymarin might serve as an effective and safe modality for the treatment of melasma.
Recurrence of melasma was reported in 1 patient (7.14%) in group 1 (silymarin 0.7%), in 1 patient (7.14%) in group 2 (silymarin 1.4%), and in 3 patients (21.4%) in group 3 (hydroquinone 4% group) after of the 6-month follow-up period. These results suggest that silymarin may decrease the recurrence rate of melasma better than hydroquinone. Besides its high safety profile, this finding represents another advantage of silymarin over hydroquinone. However, because of the small number of the studied patients and the shortterm follow-up, it is early to make a definite conclusion or recommendation in this respect.
In conclusion, topical silymarin is an effective and safe treatment modality for melasma and may represent a promising alternative to conventional hydroquinone. Longer duration of therapy is recommended for better results. Further studies on a large scale of patients and long-term follow-up are recommended to confirm these results.
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